

# Daniel J Diekema

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7790309/publications.pdf>

Version: 2024-02-01

264  
papers

29,768  
citations

3726

89  
h-index

5384

164  
g-index

265  
all docs

265  
docs citations

265  
times ranked

19166  
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem. <i>Clinical Microbiology Reviews</i> , 2007, 20, 133-163.	5.7	3,459
2	Attributable Mortality of Nosocomial Candidemia, Revisited. <i>Clinical Infectious Diseases</i> , 2003, 37, 1172-1177.	2.9	1,046
3	Epidemiology of Invasive Mycoses in North America. <i>Critical Reviews in Microbiology</i> , 2010, 36, 1-53.	2.7	799
4	Rare and Emerging Opportunistic Fungal Pathogens: Concern for Resistance beyond <i>Candida albicans</i> and <i>Aspergillus fumigatus</i> . <i>Journal of Clinical Microbiology</i> , 2004, 42, 4419-4431.	1.8	623
5	Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-Year Analysis of Susceptibilities of <i>Candida</i> Species to Fluconazole and Voriconazole as Determined by CLSI Standardized Disk Diffusion. <i>Journal of Clinical Microbiology</i> , 2010, 48, 1366-1377.	1.8	567
6	International Surveillance of Bloodstream Infections Due to <i>Candida</i> Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program. <i>Journal of Clinical Microbiology</i> , 2001, 39, 3254-3259.	1.8	475
7	Progress in Antifungal Susceptibility Testing of <i>Candida</i> spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012. <i>Journal of Clinical Microbiology</i> , 2012, 50, 2846-2856.	1.8	391
8	Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Strain ST398 Is Present in Midwestern U.S. Swine and Swine Workers. <i>PLoS ONE</i> , 2009, 4, e4258.	1.1	383
9	In Vitro Susceptibility of Invasive Isolates of <i>Candida</i> spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance. <i>Journal of Clinical Microbiology</i> , 2008, 46, 150-156.	1.8	363
10	Antifungal Susceptibilities of <i>Candida</i> Species Causing Vulvovaginitis and Epidemiology of Recurrent Cases. <i>Journal of Clinical Microbiology</i> , 2005, 43, 2155-2162.	1.8	362
11	Oxazolidinone antibiotics. <i>Lancet</i> , The, 2001, 358, 1975-1982.	6.3	356
12	Effect of Coinfection with GB Virus C on Survival among Patients with HIV Infection. <i>New England Journal of Medicine</i> , 2001, 345, 707-714.	13.9	353
13	Activities of Caspofungin, Itraconazole, Posaconazole, Ravuconazole, Voriconazole, and Amphotericin B against 448 Recent Clinical Isolates of Filamentous Fungi. <i>Journal of Clinical Microbiology</i> , 2003, 41, 3623-3626.	1.8	352
14	Epidemiology and Outcomes of Invasive Candidiasis Due to Non- <i>albicans</i> Species of <i>Candida</i> in 2,496 Patients: Data from the Prospective Antifungal Therapy (PATH) Registry 2004-2008. <i>PLoS ONE</i> , 2014, 9, e101510.	1.1	338
15	Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004-2008. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 74, 323-331.	0.8	335
16	Epidemiology of Candidemia: 3-Year Results from the Emerging Infections and the Epidemiology of Iowa Organisms Study. <i>Journal of Clinical Microbiology</i> , 2002, 40, 1298-1302.	1.8	329
17	Antimicrobial Resistance among Gram-Negative Bacilli Causing Infections in Intensive Care Unit Patients in the United States between 1993 and 2004. <i>Journal of Clinical Microbiology</i> , 2007, 45, 3352-3359.	1.8	310
18	Clinical breakpoints for the echinocandins and <i>Candida</i> revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. <i>Drug Resistance Updates</i> , 2011, 14, 164-176.	6.5	293

#	ARTICLE	IF	CITATIONS
19	Evaluation of Current Methods for Detection of Staphylococci with Reduced Susceptibility to Glycopeptides. <i>Journal of Clinical Microbiology</i> , 2001, 39, 2439-2444.	1.8	290
20	Trends in Antifungal Susceptibility of <i>Candida</i> spp. Isolated from Pediatric and Adult Patients with Bloodstream Infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. <i>Journal of Clinical Microbiology</i> , 2002, 40, 852-856.	1.8	290
21	Adverse outcomes associated with contact precautions: A review of the literature. <i>American Journal of Infection Control</i> , 2009, 37, 85-93.	1.1	283
22	Invasive Zygomycosis in Hematopoietic Stem Cell Transplant Recipients Receiving Voriconazole Prophylaxis. <i>Clinical Infectious Diseases</i> , 2004, 39, 584-587.	2.9	278
23	The changing epidemiology of healthcare-associated candidemia over three decades. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 73, 45-48.	0.8	278
24	Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-Year Analysis of Susceptibilities of <i>Candida</i> Species and Other Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing. <i>Journal of Clinical Microbiology</i> , 2007, 45, 1735-1745.	1.8	269
25	Epidemiology and Outcome of Nosocomial and Community-Onset Bloodstream Infection. <i>Journal of Clinical Microbiology</i> , 2003, 41, 3655-3660.	1.8	261
26	Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and <i>Candida</i> : Time for harmonization of CLSI and EUCAST broth microdilution methods. <i>Drug Resistance Updates</i> , 2010, 13, 180-195.	6.5	259
27	Interpretive Breakpoints for Fluconazole and <i>Candida</i> Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing. <i>Clinical Microbiology Reviews</i> , 2006, 19, 435-447.	5.7	255
28	Association of a Bundled Intervention With Surgical Site Infections Among Patients Undergoing Cardiac, Hip, or Knee Surgery. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 2162.	3.8	245
29	Role of Sentinel Surveillance of Candidemia: Trends in Species Distribution and Antifungal Susceptibility. <i>Journal of Clinical Microbiology</i> , 2002, 40, 3551-3557.	1.8	236
30	Effect of antibiotic stewardship programmes on <i>Clostridium difficile</i> incidence: a systematic review and meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1748-1754.	1.3	234
31	Antimicrobial Resistance Trends and Outbreak Frequency in United States Hospitals. <i>Clinical Infectious Diseases</i> , 2004, 38, 78-85.	2.9	232
32	Correlation of MIC with Outcome for <i>Candida</i> Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints. <i>Journal of Clinical Microbiology</i> , 2008, 46, 2620-2629.	1.8	231
33	Correlation of MIC with Outcome for <i>Candida</i> Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints. <i>Journal of Clinical Microbiology</i> , 2006, 44, 819-826.	1.8	225
34	In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of <i>Candida</i> spp. and <i>Cryptococcus neoformans</i> collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. <i>Diagnostic Microbiology and Infectious Disease</i> , 2004, 48, 201-205.	0.8	223
35	Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Triazoles and Six <i>Aspergillus</i> spp. for the CLSI Broth Microdilution Method (M38-A2 Document). <i>Journal of Clinical Microbiology</i> , 2010, 48, 3251-3257.	1.8	213
36	Azole Resistance in <i>Aspergillus fumigatus</i> Isolates from the ARTEMIS Global Surveillance Study Is Primarily Due to the TR/L98H Mutation in the <i>cyp51A</i> Gene. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4465-4468.	1.4	211

#	ARTICLE	IF	CITATIONS
37	Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-Year Analysis of Susceptibilities of Noncandidal Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing. <i>Journal of Clinical Microbiology</i> , 2009, 47, 117-123.	1.8	205
38	Oxazolidinones. <i>Drugs</i> , 2000, 59, 7-16.	4.9	198
39	<i>In Vivo</i> Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against <i>Candida</i> Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2497-2506.	1.4	198
40	<i>Candida krusei</i> , a Multidrug-Resistant Opportunistic Fungal Pathogen: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. <i>Journal of Clinical Microbiology</i> , 2008, 46, 515-521.	1.8	195
41	Characterization of blaKPC-containing <i>Klebsiella pneumoniae</i> isolates detected in different institutions in the Eastern USA. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 427-437.	1.3	194
42	Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-Year Analysis of Susceptibilities of <i>Candida</i> and Other Yeast Species to Fluconazole and Voriconazole by Standardized Disk Diffusion Testing. <i>Journal of Clinical Microbiology</i> , 2005, 43, 5848-5859.	1.8	193
43	Global Trends in the Antifungal Susceptibility of <i>Cryptococcus neoformans</i> (1990 to 2004). <i>Journal of Clinical Microbiology</i> , 2005, 43, 2163-2167.	1.8	183
44	Pneumococcal Serotypes before and after Introduction of Conjugate Vaccines, United States, 1999-2011. <i>Emerging Infectious Diseases</i> , 2013, 19, 1074-1083.	2.0	178
45	Geographic Distribution and Antifungal Susceptibility of the Newly Described Species <i>Candida orthopsilosis</i> and <i>Candida metapsilosis</i> in Comparison to the Closely Related Species <i>Candida parapsilosis</i> . <i>Journal of Clinical Microbiology</i> , 2008, 46, 2659-2664.	1.8	176
46	Diagnostic Stewardship—Leveraging the Laboratory to Improve Antimicrobial Use. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 607.	3.8	176
47	<i>In Vitro</i> Susceptibilities of <i>Candida</i> spp. to Caspofungin: Four Years of Global Surveillance. <i>Journal of Clinical Microbiology</i> , 2006, 44, 760-763.	1.8	173
48	Effects of Rapid Detection of Bloodstream Infections on Length of Hospitalization and Hospital Charges. <i>Journal of Clinical Microbiology</i> , 2003, 41, 3119-3125.	1.8	171
49	Comparative Effectiveness of Beta-Lactams Versus Vancomycin for Treatment of Methicillin-Susceptible <i>Staphylococcus aureus</i> Bloodstream Infections Among 122 Hospitals. <i>Clinical Infectious Diseases</i> , 2015, 61, 361-367.	2.9	170
50	Geographic Variation in the Susceptibilities of Invasive Isolates of <i>Candida glabrata</i> to Seven Systemically Active Antifungal Agents: a Global Assessment from the ARTEMIS Antifungal Surveillance Program Conducted in 2001 and 2002. <i>Journal of Clinical Microbiology</i> , 2004, 42, 3142-3146.	1.8	163
51	<i>Candida guilliermondii</i> , an Opportunistic Fungal Pathogen with Decreased Susceptibility to Fluconazole: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program. <i>Journal of Clinical Microbiology</i> , 2006, 44, 3551-3556.	1.8	160
52	Detection and Treatment of Bloodstream Infection: Laboratory Reporting and Antimicrobial Management. <i>Journal of Clinical Microbiology</i> , 2003, 41, 495-497.	1.8	157
53	<i>In Vitro</i> Activities of Voriconazole, Posaconazole, and Four Licensed Systemic Antifungal Agents against <i>Candida</i> Species Infrequently Isolated from Blood. <i>Journal of Clinical Microbiology</i> , 2003, 41, 78-83.	1.8	155
54	Activities of Fluconazole and Voriconazole against 1,586 Recent Clinical Isolates of <i>Candida</i> Species Determined by Broth Microdilution, Disk Diffusion, and Etest Methods: Report from The ARTEMIS Global Antifungal Susceptibility Program, 2001. <i>Journal of Clinical Microbiology</i> , 2003, 41, 1440-1446.	1.8	155

#	ARTICLE	IF	CITATIONS
55	In Vitro Activities of Anidulafungin against More than 2,500 Clinical Isolates of <i>Candida</i> spp., Including 315 Isolates Resistant to Fluconazole. <i>Journal of Clinical Microbiology</i> , 2005, 43, 5425-5427.	1.8	155
56	In Vitro Activities of Caspofungin Compared with Those of Fluconazole and Itraconazole against 3,959 Clinical Isolates of <i>Candida</i> spp., Including 157 Fluconazole-Resistant Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1068-1071.	1.4	150
57	Continued Emergence of USA300 Methicillin-Resistant <i>Staphylococcus aureus</i> in the United States: Results from a Nationwide Surveillance Study. <i>Infection Control and Hospital Epidemiology</i> , 2014, 35, 285-292.	1.0	150
58	Determining the Clinical Significance of Coagulase-Negative Staphylococci Isolated From Blood Cultures. <i>Infection Control and Hospital Epidemiology</i> , 2005, 26, 559-566.	1.0	148
59	Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins and <i>Candida</i> spp. <i>Journal of Clinical Microbiology</i> , 2010, 48, 52-56.	1.8	143
60	Changes in Pneumococcal Serotypes and Antimicrobial Resistance after Introduction of the 13-Valent Conjugate Vaccine in the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6484-6489.	1.4	136
61	In Vivo Pharmacodynamic Characterization of Anidulafungin in a Neutropenic Murine Candidiasis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 539-550.	1.4	133
62	Prevalence of the Use of Central Venous Access Devices Within and Outside of the Intensive Care Unit: Results of a Survey Among Hospitals in the Prevention Epicenter Program of the Centers for Disease Control and Prevention. <i>Infection Control and Hospital Epidemiology</i> , 2003, 24, 942-945.	1.0	129
63	Wild-Type MIC Distribution and Epidemiological Cutoff Values for <i>Aspergillus fumigatus</i> and Three Triazoles as Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Methods. <i>Journal of Clinical Microbiology</i> , 2009, 47, 3142-3146.	1.8	129
64	Wild-Type MIC Distributions and Epidemiological Cutoff Values for Amphotericin B, Flucytosine, and Itraconazole and <i>Candida</i> spp. as Determined by CLSI Broth Microdilution. <i>Journal of Clinical Microbiology</i> , 2012, 50, 2040-2046.	1.8	128
65	Minimizing the Workup of Blood Culture Contaminants: Implementation and Evaluation of a Laboratory-Based Algorithm. <i>Journal of Clinical Microbiology</i> , 2002, 40, 2437-2444.	1.8	126
66	In Vivo Pharmacodynamic Target Investigation for Micafungin against <i>Candida albicans</i> and <i>C. glabrata</i> in a Neutropenic Murine Candidiasis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3497-3503.	1.4	126
67	Incidence of Extended-Spectrum $\beta$ -Lactamase (ESBL)-Producing <i>Escherichia coli</i> and <i>Klebsiella</i> Infections in the United States: A Systematic Literature Review. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 1209-1215.	1.0	124
68	A Multicenter Intervention to Prevent Catheter-Associated Bloodstream Infections. <i>Infection Control and Hospital Epidemiology</i> , 2006, 27, 662-669.	1.0	123
69	Multicenter Comparison of the VITEK 2 Antifungal Susceptibility Test with the CLSI Broth Microdilution Reference Method for Testing Amphotericin B, Flucytosine, and Voriconazole against <i>Candida</i> spp. <i>Journal of Clinical Microbiology</i> , 2007, 45, 3522-3528.	1.8	121
70	In Vitro Survey of Triazole Cross-Resistance among More than 700 Clinical Isolates of <i>Aspergillus</i> Species. <i>Journal of Clinical Microbiology</i> , 2008, 46, 2568-2572.	1.8	121
71	Activity of MGCD290, a Hos2 Histone Deacetylase Inhibitor, in Combination with Azole Antifungals against Opportunistic Fungal Pathogens. <i>Journal of Clinical Microbiology</i> , 2009, 47, 3797-3804.	1.8	117
72	Clinical breakpoints for voriconazole and <i>Candida</i> spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 70, 330-343.	0.8	117

#	ARTICLE	IF	CITATIONS
73	In Vitro Activities of 5-Fluorocytosine against 8,803 Clinical Isolates of <i>Candida</i> spp.: Global Assessment of Primary Resistance Using National Committee for Clinical Laboratory Standards Susceptibility Testing Methods. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3518-3521.	1.4	116
74	Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. <i>International Journal of Antimicrobial Agents</i> , 2000, 13, 257-271.	1.1	114
75	Enhanced Identification of Postoperative Infections among Inpatients. <i>Emerging Infectious Diseases</i> , 2004, 10, 1924-1930.	2.0	113
76	Low Prevalence of <i>Hot Spot 1</i> Mutations in a Worldwide Collection of <i>Candida</i> Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2655-2659.	1.4	112
77	Moving Personal Protective Equipment Into the Community. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 2252.	3.8	112
78	Activities of Available and Investigational Antifungal Agents against <i>Rhodotorula</i> Species. <i>Journal of Clinical Microbiology</i> , 2005, 43, 476-478.	1.8	109
79	Surveillance of antibiotic resistance in European ICUs. <i>Journal of Hospital Infection</i> , 2001, 48, 161-176.	1.4	108
80	Look before You Leap: Active Surveillance for Multidrug-Resistant Organisms. <i>Clinical Infectious Diseases</i> , 2007, 44, 1101-1107.	2.9	108
81	Variation in Susceptibility of Bloodstream Isolates of <i>Candida glabrata</i> to Fluconazole According to Patient Age and Geographic Location in the United States in 2001 to 2007. <i>Journal of Clinical Microbiology</i> , 2009, 47, 3185-3190.	1.8	107
82	Caspofungin Activity against Clinical Isolates of Fluconazole-Resistant <i>Candida</i> . <i>Journal of Clinical Microbiology</i> , 2003, 41, 5729-5731.	1.8	106
83	Seasonality of staphylococcal infections. <i>Clinical Microbiology and Infection</i> , 2012, 18, 927-933.	2.8	106
84	In Vitro Activity of Seven Systemically Active Antifungal Agents against a Large Global Collection of Rare <i>Candida</i> Species as Determined by CLSI Broth Microdilution Methods. <i>Journal of Clinical Microbiology</i> , 2009, 47, 3170-3177.	1.8	105
85	Group B streptococci causing neonatal bloodstream infection: Antimicrobial susceptibility and serotyping results from SENTRY centers in the Western Hemisphere. <i>American Journal of Obstetrics and Gynecology</i> , 2000, 183, 859-862.	0.7	103
86	Improving Methicillin-Resistant <i>Staphylococcus aureus</i> Surveillance and Reporting in Intensive Care Units. <i>Journal of Infectious Diseases</i> , 2007, 195, 330-338.	1.9	100
87	Geographic and Temporal Trends in Isolation and Antifungal Susceptibility of <i>Candida parapsilosis</i> : a Global Assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. <i>Journal of Clinical Microbiology</i> , 2008, 46, 842-849.	1.8	96
88	Age-related trends in pathogen frequency and antimicrobial susceptibility of bloodstream isolates in North America. <i>International Journal of Antimicrobial Agents</i> , 2002, 20, 412-418.	1.1	95
89	In Vitro Susceptibility of Clinical Isolates of <i>Aspergillus</i> spp. to Anidulafungin, Caspofungin, and Micafungin: a Head-to-Head Comparison Using the CLSI M38-A2 Broth Microdilution Method. <i>Journal of Clinical Microbiology</i> , 2009, 47, 3323-3325.	1.8	94
90	Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest Methods with the CLSI Broth Microdilution Method for Echinocandin Susceptibility Testing of <i>Candida</i> Species. <i>Journal of Clinical Microbiology</i> , 2010, 48, 1592-1599.	1.8	94



#	ARTICLE	IF	CITATIONS
91	Activities of Micafungin against 315 Invasive Clinical Isolates of Fluconazole-Resistant <i>Candida</i> spp.. <i>Journal of Clinical Microbiology</i> , 2006, 44, 324-326.	1.8	91
92	An outbreak of <i>Candida parapsilosis</i> prosthetic valve endocarditis. <i>Diagnostic Microbiology and Infectious Disease</i> , 1997, 29, 147-153.	0.8	90
93	Variation in Susceptibility of Bloodstream Isolates of <i>Candida glabrata</i> to Fluconazole According to Patient Age and Geographic Location. <i>Journal of Clinical Microbiology</i> , 2003, 41, 2176-2179.	1.8	90
94	<i>Lodderomyces elongisporus</i> Masquerading as <i>Candida parapsilosis</i> as a Cause of Bloodstream Infections. <i>Journal of Clinical Microbiology</i> , 2008, 46, 374-376.	1.8	89
95	<i>Candida rugosa</i> , an Emerging Fungal Pathogen with Resistance to Azoles: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program. <i>Journal of Clinical Microbiology</i> , 2006, 44, 3578-3582.	1.8	88
96	<i>Candida guilliermondii</i> and Other Species of <i>Candida</i> Misidentified as <i>Candida famata</i> : Assessment by Vitek 2, DNA Sequencing Analysis, and Matrix-Assisted Laser Desorption Ionization Time of Flight Mass Spectrometry in Two Global Antifungal Surveillance Programs. <i>Journal of Clinical Microbiology</i> , 2013, 51, 117-124.	1.8	88
97	Identification of <i>Candida nivariensis</i> and <i>Candida bracarensis</i> in a Large Global Collection of <i>Candida glabrata</i> Isolates: Comparison to the Literature. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1216-1217.	1.8	87
98	Further Standardization of Broth Microdilution Methodology for In Vitro Susceptibility Testing of Caspofungin against <i>Candida</i> Species by Use of an International Collection of More than 3,000 Clinical Isolates. <i>Journal of Clinical Microbiology</i> , 2004, 42, 3117-3119.	1.8	85
99	Global Surveillance of In Vitro Activity of Micafungin against <i>Candida</i> : a Comparison with Caspofungin by CLSI-Recommended Methods. <i>Journal of Clinical Microbiology</i> , 2006, 44, 3533-3538.	1.8	84
100	Association of Evidence-Based Care Processes With Mortality in <i>Staphylococcus aureus</i> Bacteremia at Veterans Health Administration Hospitals, 2003-2014. <i>JAMA Internal Medicine</i> , 2017, 177, 1489.	2.6	84
101	Antibacterial properties of the CFTR potentiator ivacaftor. <i>Journal of Cystic Fibrosis</i> , 2014, 13, 515-519.	0.3	83
102	Activities of E1210 and Comparator Agents Tested by CLSI and EUCAST Broth Microdilution Methods against <i>Fusarium</i> and <i>Scedosporium</i> Species Identified Using Molecular Methods. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 352-357.	1.4	82
103	Evaluation of Postprescription Review and Feedback as a Method of Promoting Rational Antimicrobial Use: A Multicenter Intervention. <i>Infection Control and Hospital Epidemiology</i> , 2012, 33, 374-380.	1.0	82
104	In vitro susceptibilities of rare <i>Candida</i> bloodstream isolates to ravuconazole and three comparative antifungal agents. <i>Diagnostic Microbiology and Infectious Disease</i> , 2004, 48, 101-105.	0.8	81
105	Use of Epidemiological Cutoff Values To Examine 9-Year Trends in Susceptibility of <i>Aspergillus</i> Species to the Triazoles. <i>Journal of Clinical Microbiology</i> , 2011, 49, 586-590.	1.8	81
106	In Vitro Susceptibility Testing of <i>Aspergillus</i> spp.: Comparison of Etest and Reference Microdilution Methods for Determining Voriconazole and Itraconazole MICs. <i>Journal of Clinical Microbiology</i> , 2003, 41, 1126-1129.	1.8	80
107	Use of Fluconazole as a Surrogate Marker To Predict Susceptibility and Resistance to Voriconazole among 13,338 Clinical Isolates of <i>Candida</i> spp. Tested by Clinical and Laboratory Standards Institute-Recommended Broth Microdilution Methods. <i>Journal of Clinical Microbiology</i> , 2007, 45, 70-75.	1.8	80
108	Antimicrobial-Drug Use and Changes in Resistance in <i>Streptococcus pneumoniae</i> . <i>Emerging Infectious Diseases</i> , 2000, 6, 552-556.	2.0	80

#	ARTICLE	IF	CITATIONS
109	Contributions of <i>Aspergillus fumigatus</i> ATP-Binding Cassette Transporter Proteins to Drug Resistance and Virulence. <i>Eukaryotic Cell</i> , 2013, 12, 1619-1628.	3.4	78
110	Incidence and Outcomes Associated With <i>Clostridium difficile</i> Infections. <i>JAMA Network Open</i> , 2020, 3, e1917597.	2.8	78
111	Characterization of biofilms formed by <i>Candida parapsilosis</i> , <i>C. metapsilosis</i> , and <i>C. orthopsilosis</i> . <i>International Journal of Medical Microbiology</i> , 2010, 300, 265-270.	1.5	77
112	Chlorhexidine and Mupirocin Susceptibilities of Methicillin-Resistant <i>Staphylococcus aureus</i> from Colonized Nursing Home Residents. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 552-558.	1.4	76
113	An Outbreak of Severe <i>Clostridium difficile</i> Associated Disease Possibly Related to Inappropriate Antimicrobial Therapy for Community-Acquired Pneumonia. <i>Infection Control and Hospital Epidemiology</i> , 2007, 28, 212-214.	1.0	73
114	Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of <i>Candida glabrata</i> : an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 67, 162-171.	0.8	72
115	In Vitro Susceptibilities of Clinical Isolates of <i>Candida</i> Species, <i>Cryptococcus neoformans</i> , and <i>Aspergillus</i> Species to Itraconazole: Global Survey of 9,359 Isolates Tested by Clinical and Laboratory Standards Institute Broth Microdilution Methods. <i>Journal of Clinical Microbiology</i> , 2005, 43, 3807-3810.	1.8	71
116	Therapy and outcome of <i>Candida glabrata</i> versus <i>Candida albicans</i> bloodstream infection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 60, 273-277.	0.8	71
117	Unusual Fungal and Pseudofungal Infections of Humans. <i>Journal of Clinical Microbiology</i> , 2005, 43, 1495-1504.	1.8	70
118	Activity of Ceftaroline and Epidemiologic Trends in <i>Staphylococcus aureus</i> Isolates Collected from 43 Medical Centers in the United States in 2009. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4154-4160.	1.4	69
119	Multicenter Comparison of the VITEK 2 Yeast Susceptibility Test with the CLSI Broth Microdilution Reference Method for Testing Fluconazole against <i>Candida</i> spp. <i>Journal of Clinical Microbiology</i> , 2007, 45, 796-802.	1.8	68
120	Frequency of <i>FKS</i> Mutations among <i>Candida glabrata</i> Isolates from a 10-Year Global Collection of Bloodstream Infection Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 577-580.	1.4	67
121	Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2006, 55, 209-212.	0.8	66
122	<i>Mycobacterium chimaera</i> Outbreak Associated With Heater-Cooler Devices: Piecing the Puzzle Together. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 103-108.	1.0	65
123	Hospital privacy curtains are frequently and rapidly contaminated with potentially pathogenic bacteria. <i>American Journal of Infection Control</i> , 2012, 40, 904-906.	1.1	64
124	Rapid Detection of Antimicrobial-Resistant Organism Carriage: an Unmet Clinical Need. <i>Journal of Clinical Microbiology</i> , 2004, 42, 2879-2883.	1.8	63
125	Comparison of Results of Voriconazole Disk Diffusion Testing for <i>Candida</i> Species with Results from a Central Reference Laboratory in the ARTEMIS Global Antifungal Surveillance Program. <i>Journal of Clinical Microbiology</i> , 2005, 43, 5208-5213.	1.8	62
126	Cross-Resistance between Fluconazole and Ravuconazole and the Use of Fluconazole as a Surrogate Marker To Predict Susceptibility and Resistance to Ravuconazole among 12,796 Clinical Isolates of <i>Candida</i> spp. <i>Journal of Clinical Microbiology</i> , 2004, 42, 3137-3141.	1.8	61



#	ARTICLE	IF	CITATIONS
127	Wild-Type MIC Distributions and Epidemiological Cutoff Values for Posaconazole and Voriconazole and <i>Candida</i> spp. as Determined by 24-Hour CLSI Broth Microdilution. <i>Journal of Clinical Microbiology</i> , 2011, 49, 630-637.	1.8	61
128	Discontinuing contact precautions for multidrug-resistant organisms: A systematic literature review and meta-analysis. <i>American Journal of Infection Control</i> , 2018, 46, 333-340.	1.1	61
129	Selection of a Surrogate Agent (Fluconazole or Voriconazole) for Initial Susceptibility Testing of Posaconazole against <i>Candida</i> spp.: Results from a Global Antifungal Surveillance Program. <i>Journal of Clinical Microbiology</i> , 2008, 46, 551-559.	1.8	60
130	Comparison of the Broth Microdilution (BMD) Method of the European Committee on Antimicrobial Susceptibility Testing with the 24-Hour CLSI BMD Method for Testing Susceptibility of <i>Candida</i> Species to Fluconazole, Posaconazole, and Voriconazole by Use of Epidemiological Cutoff Values. <i>Journal of Clinical Microbiology</i> , 2011, 49, 845-850.	1.8	60
131	Rapid Detection of Antibiotic-Resistant Organism Carriage for Infection Prevention. <i>Clinical Infectious Diseases</i> , 2013, 56, 1614-1620.	2.9	60
132	Comparison of Results of Fluconazole Disk Diffusion Testing for <i>Candida</i> Species with Results from a Central Reference Laboratory in the ARTEMIS Global Antifungal Surveillance Program. <i>Journal of Clinical Microbiology</i> , 2004, 42, 3607-3612.	1.8	59
133	Clinical Evaluation of the Sensititre YeastOne Colorimetric Antifungal Panel for Antifungal Susceptibility Testing of the Echinocandins Anidulafungin, Caspofungin, and Micafungin. <i>Journal of Clinical Microbiology</i> , 2008, 46, 2155-2159.	1.8	59
134	Triazole and Echinocandin MIC Distributions with Epidemiological Cutoff Values for Differentiation of Wild-Type Strains from Non-Wild-Type Strains of Six Uncommon Species of <i>Candida</i> . <i>Journal of Clinical Microbiology</i> , 2011, 49, 3800-3804.	1.8	59
135	Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against <i>Candida</i> spp., using new clinical breakpoints and epidemiological cutoff values. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 73, 365-368.	0.8	59
136	Use of Micafungin as a Surrogate Marker To Predict Susceptibility and Resistance to Caspofungin among 3,764 Clinical Isolates of <i>Candida</i> by Use of CLSI Methods and Interpretive Criteria. <i>Journal of Clinical Microbiology</i> , 2014, 52, 108-114.	1.8	59
137	Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing <i>Cryptococcus neoformans</i> as determined by the CLSI broth microdilution method. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 71, 252-259.	0.8	56
138	Genetic Relatedness of Multidrug-Resistant, Methicillin (Oxacillin)-Resistant <i>Staphylococcus aureus</i> Bloodstream Isolates from SENTRY Antimicrobial Resistance Surveillance Centers Worldwide, 1998. <i>Microbial Drug Resistance</i> , 2000, 6, 213-221.	0.9	55
139	Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America. <i>Clinical Microbiology and Infection</i> , 2001, 7, 152-157.	2.8	55
140	Point-Counterpoint: To Screen or Not To Screen for Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Journal of Clinical Microbiology</i> , 2010, 48, 683-689.	1.8	55
141	Clinical significance of positive cranial bone flap cultures and associated risk of surgical site infection after craniotomies or craniectomies. <i>Journal of Neurosurgery</i> , 2011, 114, 1746-1754.	0.9	55
142	Developing a New, National Approach to Surveillance for Ventilator-Associated Events: Executive Summary. <i>Clinical Infectious Diseases</i> , 2013, 57, 1742-1746.	2.9	55
143	Effectiveness of Anidulafungin in Eradicating <i>Candida</i> Species in Invasive Candidiasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4795-4797.	1.4	53
144	Use of Epidemiological Cutoff Values To Examine 9-Year Trends in Susceptibility of <i>Candida</i> Species to Anidulafungin, Caspofungin, and Micafungin. <i>Journal of Clinical Microbiology</i> , 2011, 49, 624-629.	1.8	53

#	ARTICLE	IF	CITATIONS
145	Public Reporting of Health Care–Associated Surveillance Data: Recommendations From the Healthcare Infection Control Practices Advisory Committee. <i>Annals of Internal Medicine</i> , 2013, 159, 631.	2.0	53
146	Isavuconazole Pharmacodynamic Target Determination for <i>Candida</i> Species in an <i>In Vivo</i> Murine Disseminated Candidiasis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5642-5648.	1.4	52
147	Nosocomial Candidemia: An Ounce of Prevention Is Better Than a Pound of Cure. <i>Infection Control and Hospital Epidemiology</i> , 2004, 25, 624-626.	1.0	51
148	Strain-Relatedness of Methicillin-Resistant <i>Staphylococcus aureus</i> Isolates Recovered from Patients with Repeated Infection. <i>Clinical Infectious Diseases</i> , 2008, 46, 1241-1247.	2.9	51
149	Comparison of the Vitek Gram-Positive Susceptibility 106 Card and the MRSA-Screen Latex Agglutination Test for Determining Oxacillin Resistance in Clinical Bloodstream Isolates of <i>Staphylococcus aureus</i> . <i>Journal of Clinical Microbiology</i> , 2001, 39, 53-56.	1.8	50
150	Evaluation of the Etest and Disk Diffusion Methods for Determining Susceptibilities of 235 Bloodstream Isolates of <i>Candida glabrata</i> to Fluconazole and Voriconazole. <i>Journal of Clinical Microbiology</i> , 2003, 41, 1875-1880.	1.8	50
151	Evaluation of the Etest Method Using Mueller-Hinton Agar with Glucose and Methylene Blue for Determining Amphotericin B MICs for 4,936 Clinical Isolates of <i>Candida</i> Species. <i>Journal of Clinical Microbiology</i> , 2004, 42, 4977-4979.	1.8	49
152	Detection of <i>Staphylococcus aureus</i> Isolates with Heterogeneous Intermediate-Level Resistance to Vancomycin in the United States. <i>Journal of Clinical Microbiology</i> , 2011, 49, 4203-4207.	1.8	49
153	Antimicrobial Use Control Measures to Prevent and Control Antimicrobial Resistance in US Hospitals. <i>Infection Control and Hospital Epidemiology</i> , 2006, 27, 1088-1095.	1.0	48
154	Molecular Phylogenetic Analysis of a Geographically and Temporally Matched Set of <i>Candida albicans</i> Isolates from Humans and Nonmigratory Wildlife in Central Illinois. <i>Eukaryotic Cell</i> , 2008, 7, 1475-1486.	3.4	47
155	Validation of 24-Hour Fluconazole MIC Readings versus the CLSI 48-Hour Broth Microdilution Reference Method: Results from a Global <i>Candida</i> Antifungal Surveillance Program. <i>Journal of Clinical Microbiology</i> , 2008, 46, 3585-3590.	1.8	46
156	Evaluation of Etest Method for Determining Fluconazole and Voriconazole MICs for 279 Clinical Isolates of <i>Candida</i> Species Infrequently Isolated from Blood. <i>Journal of Clinical Microbiology</i> , 2003, 41, 1087-1090.	1.8	45
157	Association of hypocholesterolaemia with hepatitis C virus infection in HIV-infected people*. <i>HIV Medicine</i> , 2004, 5, 144-150.	1.0	45
158	Use of Anidulafungin as a Surrogate Marker To Predict Susceptibility and Resistance to Caspofungin among 4,290 Clinical Isolates of <i>Candida</i> by Using CLSI Methods and Interpretive Criteria. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3223-3229.	1.8	44
159	In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference M38-A microdilution methods for determining posaconazole MICs. <i>Diagnostic Microbiology and Infectious Disease</i> , 2003, 45, 241-244.	0.8	43
160	Varying Rates of <i>Clostridium Difficile</i> -Associated Diarrhea at Prevention Epicenter Hospitals. <i>Infection Control and Hospital Epidemiology</i> , 2005, 26, 676-679.	1.0	43
161	Candidemia surveillance in Iowa: emergence of echinocandin resistance. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 79, 205-208.	0.8	43
162	Molecular Epidemiology of Macrolide Resistance in Neonatal Bloodstream Isolates of Group B Streptococci. <i>Journal of Clinical Microbiology</i> , 2003, 41, 2659-2661.	1.8	42

#	ARTICLE	IF	CITATIONS
163	Analysis of ALS5 and ALS6 allelic variability in a geographically diverse collection of <i>Candida albicans</i> isolates. <i>Fungal Genetics and Biology</i> , 2007, 44, 1298-1309.	0.9	42
164	Reconsidering Isolation Precautions for Endemic Methicillin-Resistant <i>Staphylococcus aureus</i> and Vancomycin-Resistant <i>Enterococcus</i> . <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1395.	3.8	42
165	Multicenter Study of Anidulafungin and Micafungin MIC Distributions and Epidemiological Cutoff Values for Eight <i>Candida</i> Species and the CLSI M27-A3 Broth Microdilution Method. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 916-922.	1.4	42
166	<i>Mycobacterium chimaera</i> Infections Associated With Contaminated Heater-Cooler Devices for Cardiac Surgery: Outbreak Management. <i>Clinical Infectious Diseases</i> , 2017, 65, 669-674.	2.9	42
167	Rationale for Reading Fluconazole MICs at 24 Hours Rather than 48 Hours When Testing <i>Candida</i> spp. by the CLSI M27-A2 Standard Method. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 4175-4177.	1.4	40
168	Novel Hospital Curtains with Antimicrobial Properties: A Randomized, Controlled Trial. <i>Infection Control and Hospital Epidemiology</i> , 2012, 33, 1081-1085.	1.0	40
169	Identification and Susceptibility Profile of <i>Candida fermentati</i> from a Worldwide Collection of <i>Candida guilliermondii</i> Clinical Isolates. <i>Journal of Clinical Microbiology</i> , 2009, 47, 242-244.	1.8	39
170	Initial treatment and outcome of <i>Candida glabrata</i> versus <i>Candida albicans</i> bloodstream infection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 64, 152-157.	0.8	39
171	Ebola Virus Disease and the Need for New Personal Protective Equipment. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2495.	3.8	39
172	Comparison of the Vitek Gram-Positive Susceptibility 106 Card, the MRSA-Screen Latex Agglutination Test, and <i>mecA</i> Analysis for Detecting Oxacillin Resistance in a Geographically Diverse Collection of Clinical Isolates of Coagulase-Negative <i>Staphylococci</i> . <i>Journal of Clinical Microbiology</i> , 2001, 39, 3633-3636.	1.8	38
173	Multilaboratory Testing of Two-Drug Combinations of Antifungals against <i>Candida albicans</i> , <i>Candida glabrata</i> , and <i>Candida parapsilosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1543-1548.	1.4	38
174	Optimizing Echinocandin Dosing and Susceptibility Breakpoint Determination via <i>In Vivo</i> Pharmacodynamic Evaluation against <i>Candida glabrata</i> with and without <i>FKS</i> Mutations. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5875-5882.	1.4	38
175	Developing a New, National Approach to Surveillance for Ventilator-Associated Events. <i>American Journal of Critical Care</i> , 2013, 22, 469-473.	0.8	38
176	Antimicrobial activity of gatifloxacin compared to seven other compounds tested against Gram-positive organisms isolated at 10 cancer-treatment centers. <i>Diagnostic Microbiology and Infectious Disease</i> , 1999, 34, 37-43.	0.8	37
177	Community-Associated Methicillin-Resistant <i>Staphylococcus aureus</i> , Iowa, USA. <i>Emerging Infectious Diseases</i> , 2009, 15, 1582-1589.	2.0	37
178	Diagnosing and Reporting of Central Line-Associated Bloodstream Infections. <i>Infection Control and Hospital Epidemiology</i> , 2012, 33, 875-882.	1.0	36
179	Evaluation of Etest Method for Determining Voriconazole and Amphotericin B MICs for 162 Clinical Isolates of <i>Cryptococcus neoformans</i> . <i>Journal of Clinical Microbiology</i> , 2003, 41, 97-99.	1.8	35
180	Comparison of the Broth Microdilution Methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standards Institute for Testing Itraconazole, Posaconazole, and Voriconazole against <i>Aspergillus</i> Isolates. <i>Journal of Clinical Microbiology</i> , 2011, 49, 1110-1112.	1.8	35

#	ARTICLE	IF	CITATIONS
181	Fluoroquinolone Resistance in <i>Streptococcus pyogenes</i> . <i>Clinical Infectious Diseases</i> , 2003, 36, 380-383.	2.9	34
182	Are United States hospitals following national guidelines for the analysis and presentation of cumulative antimicrobial susceptibility data?. <i>Diagnostic Microbiology and Infectious Disease</i> , 2004, 49, 141-145.	0.8	34
183	Preventing MRSA Infections. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 1190.	3.8	32
184	Activities of Vancomycin, Ceftaroline, and Mupirocin against <i>Staphylococcus aureus</i> Isolates Collected in a 2011 National Surveillance Study in the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 740-745.	1.4	32
185	Prevalence and Genetic Relatedness of Methicillin-Susceptible <i>Staphylococcus aureus</i> Isolates Detected by the Xpert MRSA Nasal Assay. <i>Journal of Clinical Microbiology</i> , 2011, 49, 2996-2999.	1.8	31
186	Universal Precautions Training of Preclinical Students: Impact on Knowledge, Attitudes, and Compliance. <i>Preventive Medicine</i> , 1995, 24, 580-585.	1.6	30
187	Prevalence, antibiotic resistance and molecular characterisation of <i>Staphylococcus aureus</i> in pigs at agricultural fairs in the USA. <i>Veterinary Record</i> , 2012, 170, 495-495.	0.2	30
188	Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against <i>Candida</i> spp., using new clinical breakpoints and epidemiological cutoff values. <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 77, 37-40.	0.8	30
189	Lessons Learned From Hospital Ebola Preparation. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 627-631.	1.0	30
190	Increased Mortality Rates Associated with <i>Staphylococcus aureus</i> and Influenza Co-infection, Maryland and Iowa, USA1. <i>Emerging Infectious Diseases</i> , 2016, 22, 1253-1256.	2.0	29
191	Detection and Prevalence of Penicillin-Susceptible <i>Staphylococcus aureus</i> in the United States in 2013. <i>Journal of Clinical Microbiology</i> , 2016, 54, 812-814.	1.8	29
192	Evaluation of Disk Diffusion and Etest Compared to Broth Microdilution for Antifungal Susceptibility Testing of Posaconazole against Clinical Isolates of Filamentous Fungi. <i>Journal of Clinical Microbiology</i> , 2007, 45, 1322-1324.	1.8	28
193	Evaluation of Etest and Disk Diffusion Methods Compared with Broth Microdilution Antifungal Susceptibility Testing of Clinical Isolates of <i>Candida</i> spp. against Posaconazole. <i>Journal of Clinical Microbiology</i> , 2007, 45, 1974-1977.	1.8	28
194	Multicenter Comparison of the Vitek 2 Antifungal Susceptibility Test with the CLSI Broth Microdilution Reference Method for Testing Caspofungin, Micafungin, and Posaconazole against <i>Candida</i> spp. <i>Journal of Clinical Microbiology</i> , 2011, 49, 1765-1771.	1.8	28
195	Validation of 24-Hour Posaconazole and Voriconazole MIC Readings versus the CLSI 48-Hour Broth Microdilution Reference Method: Application of Epidemiological Cutoff Values to Results from a Global <i>Candida</i> Antifungal Surveillance Program. <i>Journal of Clinical Microbiology</i> , 2011, 49, 1274-1279.	1.8	28
196	Failure of Risk-Adjustment by Test Method for <i>C. difficile</i> Laboratory-Identified Event Reporting. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 109-111.	1.0	28
197	Evaluation of the NCCLS M44-P Disk Diffusion Method for Determining Susceptibilities of 276 Clinical Isolates of <i>Cryptococcus neoformans</i> to Fluconazole. <i>Journal of Clinical Microbiology</i> , 2004, 42, 380-383.	1.8	27
198	Current Practice in <i>Staphylococcus aureus</i> Screening and Decolonization. <i>Infection Control and Hospital Epidemiology</i> , 2011, 32, 1042-1044.	1.0	27

#	ARTICLE	IF	CITATIONS
199	Impact of Infectious Disease Consultation in Patients With Candidemia: A Retrospective Study, Systematic Literature Review, and Meta-analysis. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa270.	0.4	26
200	Bacterial and fungal pathogens isolated from patients with bloodstream infection: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (2012-2017). <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 97, 115016.	0.8	26
201	Genomic Analysis of Cardiac Surgery-Associated <i>Mycobacterium chimaera</i> Infections, United States. <i>Emerging Infectious Diseases</i> , 2019, 25, 559-563.	2.0	25
202	Wild-type minimum effective concentration distributions and epidemiologic cutoff values for caspofungin and <i>Aspergillus</i> spp. as determined by Clinical and Laboratory Standards Institute broth microdilution methods. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 67, 56-60.	0.8	24
203	Comparison of results of fluconazole and voriconazole disk diffusion testing for <i>Candida</i> spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 65, 27-34.	0.8	23
204	Blood and body fluid exposures during clinical training. <i>Journal of General Internal Medicine</i> , 1996, 11, 109-111.	1.3	22
205	Comparative activity of clinafloxacin and nine other compounds tested against 2000 contemporary clinical isolates from patients in United States hospitals. <i>Diagnostic Microbiology and Infectious Disease</i> , 1999, 35, 81-88.	0.8	22
206	A global evaluation of voriconazole activity tested against recent clinical isolates of <i>Candida</i> spp.. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 63, 233-236.	0.8	22
207	Evaluation of Pneumococcal Serotyping by Multiplex PCR and Quellung Reactions. <i>Journal of Clinical Microbiology</i> , 2013, 51, 4193-4195.	1.8	22
208	Long-Term Risk for Readmission, Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Infection, and Death among MRSA-Colonized Veterans. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1169-1172.	1.4	22
209	Stability of Mueller-Hinton Agar Supplemented with Glucose and Methylene Blue for Disk Diffusion Testing of Fluconazole and Voriconazole. <i>Journal of Clinical Microbiology</i> , 2004, 42, 1288-1289.	1.8	21
210	Multicenter Evaluation of the New Vitek 2 Yeast Susceptibility Test Using New CLSI Clinical Breakpoints for Fluconazole. <i>Journal of Clinical Microbiology</i> , 2014, 52, 2126-2130.	1.8	21
211	Decline in Invasive MRSA Infection. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 687.	3.8	20
212	Ebola Fever: Reconciling Planning With Risk in U.S. Hospitals. <i>Annals of Internal Medicine</i> , 2014, 161, 751.	2.0	20
213	Accuracy and Appropriateness of Antimicrobial Susceptibility Test Reporting for Bacteria Isolated from Blood Cultures. <i>Journal of Clinical Microbiology</i> , 2004, 42, 2258-2260.	1.8	19
214	Implementation of Strategies to Prevent and Control the Emergence and Spread of Antimicrobial-Resistant Microorganisms in U.S. Hospitals. <i>Infection Control and Hospital Epidemiology</i> , 2005, 26, 21-30.	1.0	19
215	Epidemiology of Methicillin-Resistant <i>Staphylococcus aureus</i> and Vancomycin-Resistant <i>Enterococcus</i> in a Rural State. <i>Infection Control and Hospital Epidemiology</i> , 2006, 27, 252-256.	1.0	19
216	Development of a Prediction Rule for Methicillin-Resistant <i>Staphylococcus aureus</i> and Vancomycin-Resistant <i>Enterococcus</i> Carriage in a Veterans Affairs Medical Center Population. <i>Infection Control and Hospital Epidemiology</i> , 2008, 29, 969-971.	1.0	19



#	ARTICLE	IF	CITATIONS
217	Screening of a Large Global <i>Aspergillus fumigatus</i> Species Complex Collection by Using a Species-Specific Microsphere-Based Luminex Assay. <i>Journal of Clinical Microbiology</i> , 2009, 47, 4171-4172.	1.8	18
218	<i>Staphylococcus aureus</i> Nasal Colonization and Colonization or Infection at Other Body Sites in Patients on a Burn Trauma Unit. <i>Infection Control and Hospital Epidemiology</i> , 2009, 30, 721-726.	1.0	18
219	Plasmid-borne <i>vga(A)</i> -encoding gene in methicillin-resistant <i>Staphylococcus aureus</i> ST398 recovered from swine and a swine farmer in the United States. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 71, 177-180.	0.8	18
220	Concordance of nasal and diabetic foot ulcer staphylococcal colonization. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 79, 85-89.	0.8	18
221	Methicillin-Resistant <i>Staphylococcus aureus</i> in Pork Production Shower Facilities. <i>Applied and Environmental Microbiology</i> , 2011, 77, 696-698.	1.4	17
222	Rising Stakes for Health Care-Associated Infection Prevention: Implications for the Clinical Microbiology Laboratory. <i>Journal of Clinical Microbiology</i> , 2017, 55, 996-1001.	1.8	17
223	Employee Health and Infection Control. <i>Infection Control and Hospital Epidemiology</i> , 1995, 16, 292-301.	1.0	15
224	Clinical Evaluation of a Frozen Commercially Prepared Microdilution Panel for Antifungal Susceptibility Testing of Seven Antifungal Agents, Including the New Triazoles Posaconazole, Ravuconazole, and Voriconazole. <i>Journal of Clinical Microbiology</i> , 2002, 40, 1694-1697.	1.8	14
225	Wild-Type MIC Distributions and Epidemiologic Cutoff Values for Fluconazole and <i>Candida</i> : Time for New Clinical Breakpoints?. <i>Current Fungal Infection Reports</i> , 2010, 4, 168-174.	0.9	14
226	Importance of Control Group Selection for Evaluating Antimicrobial Use as a Risk Factor for Methicillin-Resistant <i>Staphylococcus Aureus</i> Bacteremia. <i>Infection Control and Hospital Epidemiology</i> , 2005, 26, 634-637.	1.0	13
227	Negative pressure face shield for flexible laryngoscopy in the COVID-19 era. <i>Laryngoscope Investigative Otolaryngology</i> , 2020, 5, 718-726.	0.6	12
228	Comparing brief, covert, directly observed hand hygiene compliance monitoring to standard methods: A multicenter cohort study. <i>American Journal of Infection Control</i> , 2019, 47, 346-348.	1.1	11
229	Clinical evaluation of a dried commercially prepared microdilution panel for antifungal susceptibility testing of five antifungal agents against <i>Candida</i> spp. and <i>Cryptococcus neoformans</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2004, 50, 113-117.	0.8	10
230	Descriptive Epidemiology and Case-Control Study of Patients Colonized With Vancomycin-Resistant Enterococcus and Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Infection Control and Hospital Epidemiology</i> , 2006, 27, 913-919.	1.0	10
231	Wide Variability in the Use of Antimicrobial Lock Therapy and Prophylaxis among Infectious Diseases Consultants. <i>Infection Control and Hospital Epidemiology</i> , 2010, 31, 554-557.	1.0	10
232	Nonmenstrual Toxic Shock Syndrome Due to Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Obstetrics and Gynecology</i> , 2008, 112, 933-938.	1.2	9
233	The Epidemiology of Methicillin-Resistant <i>Staphylococcus aureus</i> on a Burn Trauma Unit. <i>Infection Control and Hospital Epidemiology</i> , 2012, 33, 1118-1125.	1.0	9
234	A randomized control trial evaluating efficacy of antimicrobial impregnated hospital privacy curtains in an intensive care setting. <i>American Journal of Infection Control</i> , 2020, 48, 862-868.	1.1	9



#	ARTICLE	IF	CITATIONS
235	DiskDiffusion Testing Using Candida sp. Colonies Taken Directlyfrom CHROMagar Candida Medium May Decrease Time Required To ObtainResults. Journal of Clinical Microbiology, 2005, 43, 3497-3499.	1.8	8
236	Variation in the Use of Procedures to Monitor Antimicrobial Resistance in U.S. Hospitals. Infection Control and Hospital Epidemiology, 2005, 26, 31-38.	1.0	8
237	A primer on data visualization in infection prevention and antimicrobial stewardship. Infection Control and Hospital Epidemiology, 2020, 41, 948-957.	1.0	8
238	Influenza Vaccination Rates, Feedback, and the Hawthorne Effect. Infection Control and Hospital Epidemiology, 2006, 27, 98-99.	1.0	7
239	Multilaboratory Testing of Antifungal Drug Combinations against Candida Species and Aspergillus fumigatus: Utility of 100 Percent Inhibition as the Endpoint. Antimicrobial Agents and Chemotherapy, 2015, 59, 1759-1766.	1.4	7
240	Multilaboratory Evaluation of <i>In Vitro</i> Antifungal Susceptibility Testing of Dermatophytes for ME1111. Journal of Clinical Microbiology, 2016, 54, 662-665.	1.8	7
241	Impact of 2018 Changes in National Healthcare Safety Network Surveillance for Clostridium difficile Laboratory-Identified Event Reporting. Infection Control and Hospital Epidemiology, 2018, 39, 886-888.	1.0	7
242	A case of recurrent episodes of Candida parapsilosis fungemia. Mycopathologia, 2006, 162, 295-298.	1.3	6
243	<i>In Vitro</i> Activity of Ceftaroline against Clinical Isolates of Streptococcus pneumoniae Recovered in 43 U.S. Medical Centers during 2010-2011. Antimicrobial Agents and Chemotherapy, 2012, 56, 3406-3408.	1.4	6
244	Long-term follow-up of post-cardiac surgery Mycobacterium chimaera infections: A 5-center case series. Journal of Infection, 2020, 80, 197-203.	1.7	6
245	Antimicrobial Therapy for Bloodstream Infection Due to Methicillin-Susceptible <i>Staphylococcus aureus</i> in an Era of Increasing Methicillin Resistance: Opportunities for Antimicrobial Stewardship. Annals of Pharmacotherapy, 2012, 46, 904-905.	0.9	5
246	Prenatal testing for infectious disease. Clinics in Laboratory Medicine, 2003, 23, 295-315.	0.7	4
247	Risk Factors for Groin Wound Infection After Femoral Artery Catheterization A Case-Control Study. Infection Control and Hospital Epidemiology, 2006, 27, 34-37.	1.0	4
248	Definitions and Epidemiology of Candida Species not Susceptible to Echinocandins. Current Fungal Infection Reports, 2011, 5, 120-127.	0.9	4
249	Bacterial Contamination of an Automated Pharmacy Robot Used for Intravenous Medication Preparation. Infection Control and Hospital Epidemiology, 2012, 33, 517-520.	1.0	4
250	Successful termination of an outbreak of <i>Mycobacterium chimaera</i> infections associated with contaminated heater-cooler devices. Infection Control and Hospital Epidemiology, 2021, 42, 471-473.	1.0	4
251	Use of Active Surveillance Cultures to Control Vancomycin-Resistant Enterococcus. Clinical Infectious Diseases, 2003, 37, 1400-1402.	2.9	3
252	Phaeoacremonium parasiticum phaeohyphomycosis in a patient with systemic lupus erythematosus treated successfully with surgical debridement and voriconazole: A case report and review of the literature. IDCases, 2014, 1, 84-88.	0.4	3

#	ARTICLE	IF	CITATIONS
253	Methicillin-resistant <i>Staphylococcus aureus</i> prevention practices in hospitals throughout a rural state. <i>American Journal of Infection Control</i> , 2014, 42, 868-873.	1.1	3
254	Contamination of health-care workers' hands with <i>Escherichia coli</i> and <i>Klebsiella</i> species after routine patient care: a prospective observational study. <i>Clinical Microbiology and Infection</i> , 2020, 26, 760-766.	2.8	3
255	Insertion site inflammation was associated with central-line-associated bloodstream infections at a tertiary-care center, 2015-2018. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 348-350.	1.0	3
256	<i>In Vitro</i> Activity of Anidulafungin and Other Agents against Esophageal Candidiasis-Associated Isolates from a Phase 3 Clinical Trial. <i>Journal of Clinical Microbiology</i> , 2010, 48, 2613-2614.	1.8	2
257	Research Agenda for Microbiome Based Research for Multidrug-resistant Organism Prevention in the Veterans Health Administration System. <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 202-209.	1.0	2
258	Infection prevention strategies for procedures performed outside operating rooms: A conceptual integrated model. <i>American Journal of Infection Control</i> , 2018, 46, 94-96.	1.1	2
259	Clinical impact of changing to an automated blood-culture system at a small community hospital. <i>Clinical Microbiology and Infection</i> , 1999, 5, 590-593.	2.8	1
260	Impact of expanded influenza post-exposure prophylaxis on healthcare worker absenteeism at a tertiary care center during the 2017-2018 season. <i>Infection Control and Hospital Epidemiology</i> , 2019, 40, 260-261.	1.0	1
261	Healthcare-associated Fungal Infections: Beyond <i>Candida</i> and <i>Aspergillus</i> . <i>Southern Medical Journal</i> , 2007, 100, 130-131.	0.3	1
262	Investigation of a <i>Candida guilliermondii</i> Pseudo-outbreak Reveals a Novel Source of Laboratory Contamination. <i>Journal of Clinical Microbiology</i> , 2017, 55, 1080-1089.	1.8	1
263	Reduction in abdominal hysterectomy surgical site infection rates after the addition of anaerobic antimicrobial prophylaxis. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 1469-1471.	1.0	0
264	Administrative coding methods impact surgical site infection rates. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 1461-1463.	1.0	0